A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma

Cancer

Volumn 118, Issue 3, 2012, Pages 660-669

  Zivanovic, Oliver ^a   Jacks, Lindsay M ^a   Iasonos, Alexia ^a   Leitao Jr , Mario M ^a   Soslow, Robert A ^a   Veras, Emanuela ^a   Chi, Dennis S ^a   Abu Rustum, Nadeem R ^a   Barakat, Richard R ^a   Brennan, Murray F ^a   Hensley, Martee L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

nomogram; prognosis; staging; survival; uterine leiomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MITOSIS INDEX; NOMOGRAM; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROBABILITY; SURVIVAL RATE; TUMOR VOLUME; UTERINE CERVIX TUMOR; UTERINE LEIOMYOSARCOMA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEIOMYOSARCOMA; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84856208980     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26333     Document Type: Article

References (43)

1. Harlow BL, Weiss NS, Lofton S,. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986; 76: 399-402.
2. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer. 1990; 66: 35-39.
3. Rose PG, Piver MS, Tsukada Y, Lau T,. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer. 1989; 63: 935-938.
4. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008; 198: 218.e1-218.e6.
5. Zivanovic O, Leitao MM, Iasonos A, et al. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer staging systems. J Clin Oncol. 2009; 27: 2066-2072.
6. Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS,. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol. 2003; 91: 209-212.
7. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant Adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985; 3: 1240-1245.
8. Reed NS, Mangioni C, Malmstrom H, et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer. 2008; 44: 808-818.
9. Rose PG, Boutselis JG, Sachs L,. Adjuvant therapy for stage I uterine sarcoma. Am J Obstet Gynecol. 1987; 156: 660-662.
10. Sorbe B, Johansson B,. Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. Int J Oncol. 2008; 32: 1111-1117.
11. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr,. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 1988; 71 (6 pt 1): 845-850.
12. Raut CP, Nucci MR, Wang Q, et al. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009; 45: 2818-2824.
13. Prat J,. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009; 104: 177-178.
14. Pelmus M, Penault-Llorca F, Guillou L, et al. Prognostic factors in early stage leiomyosarcoma of the uterus. Int J Gynecol Cancer. 2009; 19: 385-390.
15. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB,. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009; 54: 355-364.
16. Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A,. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004; 92: 648-652.
17. Mayerhofer K, Obermair A, Windbichler G, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999; 74: 196-201.
18. Hajdu SI, Shiu MH, Brennan MF,. The role of the pathologist in the management of soft tissue sarcomas. World J Surg. 1988; 12: 326-331.
19. Bell SW, Kempson RL, Hendrickson MR,. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994; 18: 535-558.
20. Soslow RA,. Uterine mesenchymal tumors: a review of selected topics. Diagn Histopathol. 2008; 14: 175-188.
21. Giuntoli RL second, Gostout BS, DiMarco CS, Metzinger DS, Keeney GL,. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med. 2007; 52: 1001-1010.
22. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD,. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008; 109: 323-328.
23. Hensley ML, Blessing JA, Mannel R, Rose PG,. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008; 109: 329-334.
24. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009; 112: 563-567.
25. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002; 20: 2824-2831.
26. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration study 002 [corrected]. J Clin Oncol. 2007; 25: 2755-2763.
27. Iasonos A, Schrag D, Raj GV, Panageas KS,. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364-1370.
28. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387.
29. Giuntoli RL, 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003; 89: 460-469.
30. Kapp DS, Shin JY, Chan JK,. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112: 820-830.
31. Gonen M, Heller G,. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005; 92: 965-970.
32. Sternberg CN,. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol. 2006; 24: 3819-3820.
33. Kattan MW,. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003; 13: 111-116.
34. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008; 26: 380-385.
35. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007; 25: 3576-3581.
36. Kattan MW, Leung DH, Brennan MF,. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002; 20: 791-796.
37. Eastham JA, Kelly WK, Grossfeld GD, Small EJ,; Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003; 62 (suppl 1): 55-62.
38. Kattan MW, Wheeler TM, Scardino PT,. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999; 17: 1499-1507.
39. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005; 23: 7005-7012.
40. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF,. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003; 21: 3647-3650.
41. Brennan MF, Kattan MW, Klimstra D, Conlon K,. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004; 240: 293-298.
42. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA,. Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001; 93: 358-366.
43. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004; 101: 1455-1462.